Traitement Cancer du rein en Israël — recevez 3 correspondances personnalisées de cliniques

Primary surgical options for kidney cancer in Israel prioritize organ-preserving techniques like partial nephrectomy and robotic-assisted surgery. Surgeons at JCI-accredited centers like Sourasky and Hadassah perform these procedures using the da Vinci system. These minimally invasive methods typically result in faster recovery and 90% oncology success rates.

• Partial nephrectomy: Removes only the tumor to preserve 90% of kidney function.
• Radical nephrectomy: Full kidney removal for tumors typically larger than 7 cm.
• Robotic-assisted surgery: Uses da Vinci Xi systems for precise excision and minimal blood loss.
• Cryoablation: Freezes small renal masses as a non-surgical alternative for high-risk patients.

Bookimed Expert Insight: Israeli urology departments frequently utilize 3D-reconstruction imaging before robotic surgery to map delicate blood vessels. Dr. Vladimir Yutkin at Hadassah Medical Center has notably performed over 300 robotic kidney procedures using this precise 3D-planning. This technology helps surgeons perform nephron-sparing surgery even on complex tumors that might require full removal elsewhere.

Patient Consensus: Patients note that scheduling for robotic surgery is remarkably fast, often secured within 1–2 weeks. Many emphasize the benefit of remote second opinions to confirm if they qualify for kidney-sparing approaches before traveling.

Israel offers advanced systemic and biological kidney cancer therapies through personalized protocols at JCI-accredited centers. Standard care integrates immunotherapy checkpoint inhibitors with targeted tyrosine kinase inhibitors. Leading facilities like Sheba Medical Center also provide innovative cellular treatments like CAR-T and tumor-infiltrating lymphocyte therapies.

• Immunotherapy combinations: Protocols include Nivolumab plus Ipilimumab or Pembrolizumab with Axitinib for metastatic cases.
• Targeted biologicals: Patients access newer agents like Savolitinib and HIF-2α inhibitors such as Belzutifan.
• Cellular oncology: Sheba Medical Center utilizes CAR-T and TIL therapies to reprogram immune cells.
• Predictive technology: Platforms like OncoHost help oncologists select the most effective drug combinations.

Bookimed Expert Insight: Israeli oncology centers like Sourasky achieve a 90% success rate by combining systemic drugs with robotic surgery. Dr. Zohar Dotan at Sheba Medical Center specifically focuses on organ-preserving techniques. This expertise allows patients to receive advanced biologicals while maintaining maximum kidney function through precision procedures.

Patient Consensus: Patients emphasize the importance of getting biomarker testing like PD-L1 early to access specific combination trials. They often note that Israel integrates these advanced global protocols faster and more affordably than many other regions.

Israel reports exceptional kidney cancer outcomes with five-year survival rates reaching 95% for localized disease. Early-stage tumors under 4 cm show cure rates near 100% following partial nephrectomy. Specialized centers like Sourasky Medical Center maintain a 90% success rate across all oncology departments.

• Early-stage survival: Patients with stage 1 tumors achieve nearly 100% cure rates via surgery.
• Localized disease: Five-year survival for cancer confined to the kidney is 90% to 95%.
• Regional spread: Survival rates for cancer in nearby tissues range from 60% to 76%.
• Cryoablation efficiency: Minimally invasive freezing techniques show a 96% efficiency rate for small masses.

Bookimed Expert Insight: Israeli oncology excellence is driven by massive surgical volumes at centers like Sheba and Sourasky. Sheba Medical Center alone performs approximately 1,800 kidney-related surgeries annually. This high frequency allows surgeons like Dr. Vladimir Yutkin to pioneer advanced 3D-reconstruction robotic partial nephrectomies. Our data shows these high-volume centers consistently achieve better organ preservation than smaller international clinics.

Patient Consensus: Patients emphasize that robotic partial nephrectomy at top centers preserves over 90% of kidney function. Many stress the importance of genetic profiling before choosing between surgery and newer immunotherapy combinations.

International patients typically stay in Israel for 10 to 14 days for kidney cancer surgery. This timeframe includes pre-operative diagnostics and surgical hospitalization. It also covers a mandatory recovery period. Surgeons require this stay to ensure patients are safe for international air travel.

• Diagnostic phase: Pre-surgical evaluations and scans usually take 3 to 4 days.
• Hospital stay: Robotic or laparoscopic procedures require 1 to 2 nights of hospitalization.
• Open surgery: Conventional open nephrectomy typically requires 3 to 5 days of inpatient care.
• Recovery period: Patients must remain in Israel for 7 days after hospital discharge.

Bookimed Expert Insight: While standard protocols suggest 10 days, data from high-volume centers like Sourasky Medical Center show complex cases often benefit from a 14-day stay. Surgeons like Dr. Vladimir Yutkin at Hadassah use 3-D mapping for partial nephrectomies. These advanced robotic techniques significantly stabilize recovery early on. Choosing a center with an on-site hotel, such as Sheba Medical Center, simplifies the mandatory week of post-operative monitoring.

Patient Consensus: Patients emphasize staying within 15 minutes of the clinic for the first two weeks. Many note that surgical drains might stay in longer than expected, requiring an extra few days before flying.

Leading Israeli hospitals including Sourasky Medical Center, Sheba Medical Center, and Hadassah Medical Center routinely perform robotic nephrectomy for international patients. These JCI-accredited facilities utilize the da Vinci surgical system. This approach offers high precision for complex kidney cancer cases while prioritizing patient safety.

• Sourasky Medical Center: Ranked among the world's most advanced hospitals by Newsweek magazine.
• Sheba Medical Center: Serves over 2,000,000 patients annually and pioneered robotic urologic surgery.
• Hadassah Medical Center: Offers unique robotic partial nephrectomies using three-dimensional kidney reconstruction.
• Specialist expertise: Dr. Vladimir Yutkin has performed over 300 robotic kidney and bladder surgeries.

Bookimed Expert Insight: Israeli oncology centers like Hadassah differentiate themselves through specialized technology like 3D kidney reconstruction for partial nephrectomies. This level of detail is rare. While many clinics offer standard robotic surgery, choosing a facility with 3D planning may improve the chances of saving healthy kidney tissue during tumor removal.

Patient Consensus: Patients note it is important to contact international departments directly to verify if a specific case qualifies for the da Vinci system. Many emphasize confirming the surgeon's personal volume of robotic procedures before traveling.

Cryoablation is a primary non-surgical alternative for small kidney tumors under 4 cm in Israel. This minimally invasive technique uses extreme cold to destroy malignant cells while preserving healthy tissue. It offers an 88.7% recurrence-free rate for tumors reaching up to 5 cm.

• Target tumor size: Most effective for Stage T1a renal masses smaller than 4 cm.
• Recovery advantage: Patients typically return to normal activities within 1 to 2 weeks.
• Hospital stay: Often performed as an outpatient procedure or requires only short-stay observation.
• Success rate: Israeli clinical studies report approximately 90% success for small peripheral tumors.
• Specialist expertise: Experts like Dr. Haim Matskin at Sourasky Medical Center specialize in cryotherapy.

Bookimed Expert Insight: While many patients seek cryoablation for its 95% safety profile, success depends heavily on tumor location. Data from top centers like Sheba and Sourasky shows that peripheral tumors are ideal for probes. Central tumors located near the renal pelvis often require robotic partial nephrectomy instead. Always confirm your tumor's exact position via CT before choosing this cold-based therapy.

Patient Consensus: Patients value how this procedure preserves kidney function much better than traditional surgery. They note that while 5% to 10% may need a second session, the lower complication risk is a significant relief.

Major Israeli medical centers offer clinical trials for metastatic kidney cancer, providing access to novel immunotherapies and targeted agents. Facilities like Sheba Medical Center and Sourasky Medical Center manage extensive research units. These programs often prioritize stage 4 patients seeking innovative alternatives to standard care protocols.

• Available phases: Centers conduct phase 1, 2, and 3 trials for kidney cancer.
• Research focus: Trials investigate immune checkpoint inhibitors and novel biological antitumor targeted therapies.
• Leading investigators: Prof. David Sarid and Dr. Irina Stepfansky lead oncology research at Sourasky.
• Trial costs: Medications provided within clinical trials are typically free for eligible participants.

Bookimed Expert Insight: While many patients focus on large public hospitals, our data shows that specialized units like the Riva Koschitzky Oncology Clinical Research Unit at Sheba collaborate directly with MD Anderson in the US. This partnership often brings specific protocols to Israel before they are widely available in other international regions. This makes Sheba a primary destination for patients seeking the most recent western research standards.

Patient Consensus: Patients emphasize the importance of securing a performance status (PS) score and biomarker tests early. They note that even if you match the trial criteria, eligibility is strict and often excludes those with stable disease or brain metastases.